SpeeDx partner with Neogen Diagnostik for distribution in Turkey
SpeeDx have announced signing a new distribution partner, further extending customer access to market-leading SpeeDx ResistancePlu...
18 March, 2021SpeeDx ResistancePlus® diagnostics detect the infecting organism and antibiotic susceptibility or resistance markers – empowering clinicians to make informed patient treatment decisions.
Resistance Guided Therapy (RGT) uses advances in diagnostic technology to help clinicians choose the best targeted therapy for individual patients based on the resistance status of their infection.
Strategies for controlling many STIs are dependent on the availability of inexpensive yet highly effective antibiotics. As antimicrobial resistance rates rise in these infections it even more important to use our limited antibiotics more wisely.
Guidelines for management of STIs caused by Mycoplasma genitalium and Neisseria gonorrhoeae increasingly recommend RGT to help:
Declining cure rates when employing detection-only practices for M. genitalium addressed with implementation of RGT, increasing cure rates for macrolide susceptible populations to 95% and total population cure rate over 92%.1
Improve cure rate and simplify patient management.
ResistancePlus® tests give your laboratory a competitive advantage. Now you can offer your clinicians more than just detection. The combination of resistance data with infection detection in a single-well test, enables RGT for improved patient management.
ResistancePlus® tests combine organism detection with genetic markers linked to antibiotic susceptibility or resistance. PlexPCR® tests combine multiple, clinically relevant infectious disease targets into a single test solution.
Single well qPCR test detecting Neisseria gonorrhoeae and markers linked to ciprofloxacin susceptibility
Single well qPCR test detecting and differentiating HSV-1, HSV-2, VZV & Treponema pallidum (Syphilis)
Single well qPCR test detecting Mycoplasma genitalium and markers linked to macrolide resistance
Single well qPCR test detecting and differentiating HSV-1, HSV-2 and VZV
2 well qPCR test detecting and differentiating 11 respiratory viruses
Cartridge-based test detecting M. genitalium and macrolide resistance markers
Deliver innovative clinical diagnostics to improve patient outcomes
SpeeDx have announced signing a new distribution partner, further extending customer access to market-leading SpeeDx ResistancePlu...
18 March, 2021Roche customers will now have even more opportunities to utilise ResistancePlus® tests to support clinically important treatment d...
18 March, 2021Syphilis remains an important public health concern due to global case increases. In Australia, the largest syphilis outbreak ever...
03 February, 2021Our mission is to deliver innovative clinical diagnostics to improve patient outcomes. Meet the SpeeDx Team, learn about our key collaborations and partnerships, and join our passion to change the face of diagnostics.
References:
1Read TRH et al. Clinical Infectious Diseases 2019; 68(4):554-560
2Harris SR et al. Lancet Infect Dis Published online May 15th 2018
3Lahra MM et al. Australian Gonococcal Surveillance Programme annual report, 2015
4Heffernan H et al. Antimicrobial resistance and molecular epidemiology of gonococci in NZ, 2014-5
5Kirkcaldy RD et al. MMWR Surveillance Summaries July 15, 2016 / 65(7);1–19